Citi opened a “90-day negative catalyst watch” following Roche’s positive share price reaction to the leaked data yesterday. The firm estimates the probability of SKY-01 showing statistical significance at the final overall survival analysis, expected in December 2023, is 50%. The statistical design of SKY-01 is likely sub-optimal for capturing the late treatment effect evident in SKY-01 compared the early curve divergence seen in CITYSCAPE, the analyst tells investors in a research note. Citi keeps a Buy rating on Roche with a CHF 350 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RHHBY:
- Roche’s TIGIT results have positive readthrough to Arcus, says BTIG
- Truist ‘optimistic’ on Compugen’s approach after Roche data leak
- iTeos should be up ‘sharply’ on Roche data, says Piper Sandler
- iTeos jumps after Roche inadvertently publishes positive TIGIT data
- Roche inadvertently publishes positive results from drug study, FT reports